Roche announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring, or CGM, solution. “This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy,” the company stated. “Maintaining optimal blood glucose levels and preventing adverse glycaemic episodes remains a complex task for people living with diabetes, often necessitating up to 180 therapy decisions a day. Our novel CGM solution with its predictive algorithms will help address significant unmet needs associated with diabetes management, empowering users to take control of their condition and live better and healthier lives,” said Matt Sause, CEO of Roche Diagnostics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
- Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
- Arcus Biosciences drops 6% after Roche lung cancer failure
- Roche failure likely worst case for Arcus study, says Cantor Fitzgerald
- Genentech announces FDA approval of Vabysmo 6.0 mg single-dose prefilled syringe
Questions or Comments about the article? Write to editor@tipranks.com